Co-Diagnostics (CODX) could make huge moves soon
Co-Diagnostics (CODX) currently trades at $8.78 and has fallen by 0.23% today. CODX went down $0.02 from the previous closing price of $8.80. The high forecast for Co-Diagnostics is $20.00 and the low is $5.00. The company’s market cap is $241.46 million with a 52 week high of $21.75 and a 52 week low of $0.69. CODX has changed in price by 7.73 per share in the last 12 months. On April 3, its Logix Smart COVID-19 test kit was granted Emergency Use Authorization (EUA) by the FDA for use in detecting the deadly virus. The test has already shown 100% sensitivity and 100% specificity in identifying SARS-CoV-2 without showing any cross-reactivity with other coronaviruses. Not to mention the test is easy to use as well as interpret, and the number of test shipments is steadily rising.
Co-Diagnostics has a weak EPS of -0.37. This means the company lost $-0.37 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article.
Co-Diagnostics, Inc. is a molecular diagnostics company with unique, patented Polymerase Chain Reaction (“PCR”) testing technology. A Utah corporation headquartered in Salt Lake City, Utah, we commercialize our innovative patented and patent-pending technology through sales, development and licensing, to quickly develop molecular diagnostics that are more cost-efficient and perform better than traditional technologies of the past.